Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Oral Decitabine and Tetrahydrouridine (THU) in Patients With High Risk Sickle Cell Disease

NCT01685515 is registered in ClinicalTrials.gov with Yogen Saunthararajah as lead sponsor.

NCT NCT01685515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01685515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Oral Decitabine and Tetrahydrouridine (THU) in Patients With High Risk Sickle Cell Disease
Lead sponsor
Yogen Saunthararajah
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2012
Completion date
June 30, 2018
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease